Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M3814 with radiotherapy in advanced solid tumors and stage III NSCLC
NL-OMON47619Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of peposertib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and lymphoma (3 arms), sponsored by Merck KGaA. Primary endpoints: Dose-limiting toxicities in Phase Ia, Dose-limiting toxicities in first 3 Phase Ib subjects and 2 more. Started Sep 2015; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)lymphoma
Beyond the preview
Go deeper on NL-OMON47619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47619.